A single-arm study of systemic and sub-Tenon chemotherapy for Groups C and D intraocular retinoblastoma: A Children’s Oncology Group study (ARET 0231)

Jubran RF, Villablanca JG, Krailo M, Piao J, Huang L, Murphree AL, O’Brien J, Gombos D, Shields CL, Meadows A, Chintagumpala M. A single-arm study of systemic and sub-Tenon chemotherapy for Groups C and D intraocular retinoblastoma: A Children’s Oncology Group study (ARET 0231). Pediatr Blood Cancer. 2020 Sep;67(9):e28502. doi: 10.1002/pbc.28502. Epub 2020 Jun 26. PubMed PMID: 32589362; PubMed Central PMCID: PMC7857974.

Eyes with Group D intraocular retinoblastoma have low salvage rates. A pilot study showed safety and efficacy of sub-Tenon’s fascia carboplatin with systemic chemotherapy supporting further study. Children with newly diagnosed bilateral intraocular retinoblastoma with at least one remaining Group C or D eye were treated with 6 courses ofcarboplatin/etoposide/vincristine(CEV) with sub-Tenon’s fascia carboplatin for Group C/D eyes during courses 2–4. Local ophthalmic therapy started at course 3. The primary study objective was to determine the 1-year failure rate of Group D eyes.